Clinical Trial Update: Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing NLX-112 vs placebo for safety, tolerability, and preliminary efficacy in L-dopa-induced dyskinesia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medication-induced Dyskinesia

Drugs mentioned

• NLX-112

Snippet

Sponsor: Neurolixis SAS | Conditions: Medication-Induced Dyskinesia | Phase 2 | Status: COMPLETED | Results posted: 2024-04-23